Treatment of postmenopausal osteoporosis with calcitriol or calcium - PubMed (original) (raw)
Clinical Trial
. 1992 Feb 6;326(6):357-62.
doi: 10.1056/NEJM199202063260601.
Affiliations
- PMID: 1729617
- DOI: 10.1056/NEJM199202063260601
Free article
Clinical Trial
Treatment of postmenopausal osteoporosis with calcitriol or calcium
M W Tilyard et al. N Engl J Med. 1992.
Free article
Abstract
Background and methods: Osteoporosis is a common problem whose management is controversial. To evaluate the efficacy and safety of calcitriol (1,25-dihydroxyvitamin D3) in the treatment of postmenopausal osteoporosis, we conducted a three-year prospective, multicenter, single-blind study in 622 women who had one or more vertebral compression fractures. The women were randomly assigned to receive treatment with calcitriol (0.25 micrograms twice a day) or supplemental calcium (1 g of elemental calcium daily) for three years. New vertebral fractures were detected by means of lateral roentgenography of the spine each year, and calcium absorption was measured in 392 of the women.
Results: The women who received calcitriol had a significant reduction in the rate of new vertebral fractures during the second and third years of treatment, as compared with the women who received calcium (second year, 9.3 vs. 25.0 fractures per 100 patient-years; third year, 9.9 vs. 31.5 fractures per 100 patient-years; P less than 0.001). This effect was evident only in women who had had five or fewer vertebral fractures at base line (second year, 5.2 vs. 25.3 fractures per 100 patient-years; third year, 4.2 vs. 31.0 fractures per 100 patient-years; P less than 0.0001). The groups also differed significantly in the number of peripheral fractures; 11 such fractures occurred in 11 women in the calcitriol group, whereas 24 occurred in 22 women in the calcium group (P less than 0.05). There was no significant difference between the groups in the incidence of side effects requiring withdrawal of treatment (8.6 percent in the calcitriol group vs. 6.5 percent in the calcium group).
Conclusions: Continuous treatment of postmenopausal osteoporosis with calcitriol for three years is safe and significantly reduces the rate of new vertebral fractures in women with this disorder.
Comment in
- Osteoporosis and its treatment.
Chesnut CH 3rd. Chesnut CH 3rd. N Engl J Med. 1992 Feb 6;326(6):406-8. doi: 10.1056/NEJM199202063260609. N Engl J Med. 1992. PMID: 1729625 Clinical Trial. No abstract available.
Similar articles
- Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M. Liberman UA, et al. N Engl J Med. 1995 Nov 30;333(22):1437-43. doi: 10.1056/NEJM199511303332201. N Engl J Med. 1995. PMID: 7477143 Clinical Trial. - Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC 3rd, Yanover MJ, et al. Watts NB, et al. N Engl J Med. 1990 Jul 12;323(2):73-9. doi: 10.1056/NEJM199007123230201. N Engl J Med. 1990. PMID: 2113611 Clinical Trial. - Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkänen L, Kenraali J, Aropuu S, Kanis JA. McCloskey E, et al. J Bone Miner Res. 2004 May;19(5):728-36. doi: 10.1359/JBMR.040116. Epub 2004 Jan 19. J Bone Miner Res. 2004. PMID: 15068495 Clinical Trial. - Calcitriol. A review of its use in the treatment of postmenopausal osteoporosis and its potential in corticosteroid-induced osteoporosis.
Dechant KL, Goa KL. Dechant KL, et al. Drugs Aging. 1994 Oct;5(4):300-17. doi: 10.2165/00002512-199405040-00006. Drugs Aging. 1994. PMID: 7827399 Review. - Calcitriol and postmenopausal osteoporosis.
Sambrook P. Sambrook P. Med J Aust. 1992 Sep 21;157(6):364-6. doi: 10.5694/j.1326-5377.1992.tb137239.x. Med J Aust. 1992. PMID: 1447982 Review. No abstract available.
Cited by
- Nodakenin Ameliorates Ovariectomy-Induced Bone Loss by Regulating Gut Microbiota.
Liu C, Chen J, Wang Z, Li Y, Zhang Y, Li G. Liu C, et al. Molecules. 2024 Mar 11;29(6):1240. doi: 10.3390/molecules29061240. Molecules. 2024. PMID: 38542877 Free PMC article. - Refracture following vertebral fragility fracture when bone fragility is not recognized: summarizing findings from comparator arms of randomized clinical trials.
Porcu G, Biffi A, Ronco R, Adami G, Alvaro R, Bogini R, Caputi AP, Frediani B, Gatti D, Gonnelli S, Iolascon G, Lenzi A, Leone S, Michieli R, Migliaccio S, Nicoletti T, Paoletta M, Pennini A, Piccirilli E, Rossini M, Tarantino U, Cianferotti L, Brandi ML, Corrao G. Porcu G, et al. J Endocrinol Invest. 2024 Apr;47(4):795-818. doi: 10.1007/s40618-023-02222-0. Epub 2023 Nov 3. J Endocrinol Invest. 2024. PMID: 37921990 Free PMC article. Review. - Bifidobacterium lactis Probio-M8 improves bone metabolism in patients with postmenopausal osteoporosis, possibly by modulating the gut microbiota.
Zhao F, Guo Z, Kwok LY, Zhao Z, Wang K, Li Y, Sun Z, Zhao J, Zhang H. Zhao F, et al. Eur J Nutr. 2023 Mar;62(2):965-976. doi: 10.1007/s00394-022-03042-3. Epub 2022 Nov 5. Eur J Nutr. 2023. PMID: 36334119 Clinical Trial. - Effects of vitamin D3 release from 3D printed calcium phosphate scaffolds on osteoblast and osteoclast cell proliferation for bone tissue engineering.
Vu AA, Bose S. Vu AA, et al. RSC Adv. 2019;9(60):34847-34853. doi: 10.1039/c9ra06630f. Epub 2019 Oct 29. RSC Adv. 2019. PMID: 35474960 Free PMC article. - A Novel Vitamin D Receptor Agonist, VS-105, Improves Bone Mineral Density without Affecting Serum Calcium in a Postmenopausal Osteoporosis Rat Model.
Wu-Wong JR, Wessale JL, Chen YW, Chen T, Oubaidin M, Atsawasuwan P. Wu-Wong JR, et al. J Explor Res Pharmacol. 2020 Dec;5(4):73-80. doi: 10.14218/jerp.2020.00020. Epub 2020 Nov 6. J Explor Res Pharmacol. 2020. PMID: 34589670 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources